All In Biotech

Drug Trial Radar · NCT07156175

A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remission

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of SAR444336 in Participants With Microscopic Colitis in Clinical Remission With Budesonide

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

60

Actual

Start

Oct 14, 2025

Primary completion

Apr 8, 2027

Study completion May 6, 2027

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Sep 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a parallel, placebo-controlled, multicenter, randomized, double-blind, Phase 2, proof of concept study. The study aims to evaluate the efficacy and safety of SAR444336 in adult participants with microscopic colitis. Participants are required to have a histologically confirmed diagnosis of microscopic colitis, be in clinical remission and be receiving budesonide therapy. The overall study duration is approximately 32 weeks.

Conditions

  • Microscopic Colitis

Interventions

  • SAR444336Drug

    Pharmaceutical form:Solution for injection -Route of administration:Subcutaneous

  • PlaceboDrug

    Pharmaceutical form:Solution for injection -Route of administration:Subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with sustained steroid-free clinical remissionTime frame: up to week 24

Locations

24 sites in 9 countries. Site status is shown where the registry gives one.

  • Investigational Site Number : 0560001

    Leuven, Belgium

  • Investigational Site Number : 2080003

    Aarhus, Denmark

  • Investigational Site Number : 2080002

    Hvidovre, Denmark

  • Investigational Site Number : 2500001

    Créteil, France

  • Investigational Site Number : 2500002

    Montfermeil, France

  • Investigational Site Number : 2500003

    Pessac, France

  • Investigational Site Number : 2760001

    Frankfurt, Germany

  • Investigational Site Number : 2760005

    Ludwigshafen, Germany

  • Investigational Site Number : 2760003

    Tübingen, Germany

  • Investigational Site Number : 2760004

    Ulm, Germany

  • Investigational Site Number : 3480002

    Budapest, Hungary

  • Investigational Site Number : 3480003

    Székesfehérvár, Hungary

  • Investigational Site Number : 3800004

    Milan, Milano, Italy

  • Investigational Site Number : 3800001

    Padua, Padova, Italy

  • Investigational Site Number : 3800003

    Rome, Roma, Italy

  • Investigational Site Number : 3800002

    Turin, Torino, Italy

  • Investigational Site Number : 6160004

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

  • Investigational Site Number : 6160003

    Warsaw, Masovian Voivodeship, Poland

  • Investigational Site Number : 6160002

    Warsaw, Masovian Voivodeship, Poland

  • Investigational Site Number : 7520001

    Linköping, Sweden

  • Investigational Site Number : 7520002

    Stockholm, Sweden

  • Investigational Site Number : 7520003

    Stockholm, Sweden

  • Investigational Site Number : 8260002

    Cambridge, Cambridgeshire, United Kingdom

  • Investigational Site Number : 8260001

    Oxford, Oxfordshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.